Adipotide (Prohibitin‑TP01)

Adipotide (Prohibitin‑TP01) is a chimeric, adipose‑vasculature–targeted peptidomimetic that homes to prohibitin/annexin A2 on white adipose tissue endothelium and delivers a pro‑apoptotic D‑(KLAKLAK)2 motif. In obese primates it produced rapid fat loss with improved insulin resistance, but development halted after an early Phase 1 oncology trial; kidney safety signals (reversible proximal tubule changes) remain a key concern.

• White Adipose Reduction
• Insulin Sensitivity
• Peripheral Approach

Rapid fat‑mass reduction in obese non‑human primates with improved insulin sensitivity; direct WAT vascular targeting.

CKGGRAKDC homes to prohibitin/annexin A2 on white‑fat endothelium; the linked D‑(KLAKLAK)2 disrupts mitochondrial membranes after internalization, triggering localized endothelial apoptosis and adipocyte loss.

Research protocols from published literature — not dosing recommendations.

• Semaglutide (GLP‑1 RA) — Monitor Combination: Potential additive dehydration/GI effects; monitor renal function (adipotide has dose‑related proximal tubule effects).
• Tirzepatide (GLP‑1/GIP RA) — Monitor Combination: Overlapping weight‑loss effects; monitor kidney function, volume status, and electrolytes.
• Cagrilintide (Amylin analog) — Unknown: No clinical data on co‑administration; mechanisms differ (satiety vs. adipose vasculature).
• AOD‑9604 — Unknown: No published data on combined use or pharmacodynamic interaction.
• BPC‑157 — Compatible: No known direct interaction; distinct mechanisms and targets.
• CJC‑1295 / Ipamorelin — Use Caution: Metabolic effects may confound body‑composition endpoints; consider staging or separating protocols.
• Melanotan II — Requires Timing: Theoretical vascular/pressor effects; if studied together, stagger dosing and monitor BP and hydration.
• Nephrotoxic drugs (e.g., high‑dose NSAIDs, aminoglycosides) * — Avoid Combination: Adipotide shows dose‑dependent proximal tubule injury in primates; avoid additional renal insults.

Supplies:

• Lyophilized peptide vial
• Bacteriostatic water (BAC water)
• Alcohol swabs & sterile syringes
• Insulin syringes (0.5–1 mL)

1. 1Sanitize hands and workspace; swab vial septum.
2. 2Inject BAC water slowly down the vial wall; do not jet onto powder.
3. 3Gently swirl until fully dissolved (do not shake).
4. 4Label with concentration/date; store at 2–8°C; discard per lab SOP.

Week 1–2: Early reduction in abdominal circumference. Week 2–4: Progressive weight/fat‑mass decline. Recovery: Partial rebound possible after discontinuation. Common lab signals: mild creatinine rise, electrolyte shifts.

Not FDA‑approved; investigational/educational only.. Monitor serum creatinine, BUN, urinalysis, electrolytes weekly in animal studies.. Kidney: dose‑dependent, largely reversible proximal tubule changes observed in primates.. Avoid dehydration; consider temporarily pausing if creatinine rises persistently.. Pregnancy/lactation: not studied; avoid..

Not FDA‑approved; investigational/educational only.. Monitor serum creatinine, BUN, urinalysis, electrolytes weekly in animal studies.. Kidney: dose‑dependent, largely reversible proximal tubule changes observed in primates.. Avoid dehydration; consider temporarily pausing if creatinine rises persistently.. Pregnancy/lactation: not studied; avoid..

Adipotide (Prohibitin‑TP01) should be stored at 2–8°C.